PTAB Nixes Two More Humira Dosing Patents Following Coherus’ Challenges

The PTO invalidated two more AbbVie patents on dosing regimens for Humira after continuing challenges from Coherus, which plans to submit its biosimilar version of the blockbuster drug for FDA approval later this year.
Source: Generic Line